Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/341614
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Could SARS-CoV-1 Vaccines in the Pipeline Have Contributed to Fighting the COVID-19 Pandemic? Lessons for the Next Coronavirus Plague |
Autor: | López, Daniel; García-Peydró, Marina CSIC ORCID | Palabras clave: | HLA Vaccines Cross-reactivity T cells SARS-CoV-2 |
Fecha de publicación: | 27-dic-2023 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Biomedicines 12(1): 62 (2024) | Resumen: | SARS-CoV-2 caused the devastating COVID-19 pandemic, which, to date, has resulted in more than 800 million confirmed cases and 7 million deaths worldwide. The rapid development and distribution (at least in high-income countries) of various vaccines prevented these overwhelming numbers of infections and deaths from being much higher. But would it have been possible to develop a prophylaxis against this pandemic more quickly? Since SARS-CoV-2 belongs to the subgenus sarbecovirus, with its highly homologous SARS-CoV-1, we propose here that while SARS-CoV-2-specific vaccines are being developed, phase II clinical trials of specific SARS-CoV-1 vaccines, which have been in the pipeline since the early 20th century, could have been conducted to test a highly probable cross-protection between SARS-CoV-1 and SARS-CoV-2. | Versión del editor: | https://doi.org/10.3390/biomedicines12010062 | URI: | http://hdl.handle.net/10261/341614 | DOI: | 10.3390/biomedicines12010062 | E-ISSN: | 2227-9059 |
Aparece en las colecciones: | (CBM) Artículos (PTI Salud Global) Colección Especial COVID-19 |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Could SARS-CoV-1_Lopez_PV_Art.pdf | 211,6 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
Page view(s)
17
checked on 23-abr-2024
Download(s)
13
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons